NCT06907615: An ongoing trial by Shanghai Henlius Biotech
This trial is ongoing. It must report results 3 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06907615 |
|---|---|
| Title | An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 9, 2025 |
| Completion date | April 20, 2028 |
| Required reporting date | April 20, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |